1 TITLE PAGE

- 2 Title of the article Weight loss in patients with COVID-19 and Influenza in comorbidity with
- 3 NCDs: a pilot prospective clinical trial.
- 4 **Running head:** Weight loss for COVID-19/Influenza: a pilot prospective clinical trial

5 AUTHORS

- 6 Kuat Oshakbayev (corresponding author)^{1, 10}, MD, PhD, DMSc, professor; Aigul Durmanova²
- 7 , MD, PhD, DMSc; Alisher Idrisov ³, MD, PhD, DMSc; Zulfiya Zhankalova ⁴, MD, PhD, DMSc;
- 8 Gulnara Bedelbayeva ⁵ MD, PhD, DMSc, associate professor; Meruyert Gazaliyeva ⁶, MD,
- 9 PhD, DMSc, professor; Attila Tordai ⁷, PhD, DSc, professor; Altay Nabiyev ⁸, MD, PhD;
- 10 Bibazhar Dukenbayeva ^{9, 10}, MD, PhD, associate professor.

11 Affiliations of authors:

- ¹² ¹ University medical center, Internal Medicine Department. Street Syganak, 46, 010000,
- 13 Astana, Kazakhstan. Mob. phone: +7-701-3999394; e-mail: okp.kuat@gmail.com;

14 kuat.oshakbayev@umc.org.kz

- ¹⁵ ² University medical center, Internal Medicine Department. Street Syganak, 46, 010000,
- Astana, Kazakhstan. Mob. phone: +7-7772637736; E-mail: aiguldurmanova@mail.ru
- ¹⁷ ³Medical University Astana, Department of Endocrinology, Astana, Kazakhstan. Tel.mob.:
- 18 +7-7015140583; E-mail: aliser73@mail.ru
- 19 ⁴ Asfendiyarov Kazakh National Medical University, Department of General Medical Practice
- 20 #1. Street Tole Bi, 94. Almaty 050000, Kazakhstan). Tel.mob.: +77026043940; E-mail:
- 21 z.zhankalova@kaznmu.kz; zulfiya-zhankalo@mail.ru
- ⁵ Asfendiyarov Kazakh National Medical University, Faculty of postgraduate education. Street
- 23 Tole Bi, 94. Almaty 050000, Kazakhstan). Tel.mob.: +77772281581; E-mail:
- 24 bedelbaeva@mail.ru
- 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ⁶ Medical University Karaganda, Faculty of Internal Medicine. Street Gogol, 40, Karaganda,
- 27 Kazakhstan. Tel.mob.: +7-7075555514; e-mail: Gazalieva@qmu.kz;
- 28 gazaliyeva@yandex.ru
- ²⁹ ⁷ Semmelweis University, Dept. Transfusion Medicine. H-1088 Budapest, Vas u. 17,
- 30 Hungary; email: tordai.attila@med.semmelweis-univ.hu
- ⁸ University medical center, Internal Medicine Department. Street Syganak, 46, 010000,
- Astana, Kazakhstan. Mob. phone: +7 701 908 2725; e-mail: a.nabiyev@umc.org.kz
- ³³ ⁹ Medical University Astana, Faculty of pathology and forensic medicine, Astana, Kazakhstan.
- 34 Tel.mob.: +7-7013999141; E-mail: dukenbaeva74@gmail.com
- ¹⁰ ANADETO medical center, st. Kerey, Zhanibek khans, 22, Astana, 010000, Kazakhstan.
- 36 Corresponding Author: Kuat Oshakbayev. University medical center, Internal Medicine
- 37 Department. The Republic of Kazakhstan, 010000, Astana, str. Syganak, 2. Mob. phone: +7-
- 38 7013999394. Email: okp.kuat@gmail.com; kuat.oshakbayev@umc.org.kz
- 39 **Funding:** This research was supported by Ministry of Education and Science of the Republic
- 40 of Kazakhstan (Grant for 2018-2021 years with trial registration AP05135241, National
- 41 Center for Scientific and Technical Information of the Republic of Kazakhstan. K.O., a PI of
- 42 the project, is supported by the Ministry of health of the Republic of Kazakhstan, 2020-2021.
- 43 Word count (excluding abstract and references): 4150
- 44 Number of Tables: 2
- 45 Number of Figures: 1
- 46 Number of Photos: 0
- 47 **Number of References**: 73.

48 ABSTRACT

Background COVID and Influenza with non-communicable chronic diseases (NCDs)
 complicate the diagnosis, treatment, prognosis, and increase mortality rate. The aim: to

evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile,
 metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID
 and Influenza in comorbidity with NCDs.

54 Methods: A 6-week open, pilot prospective clinical trial including 62 adult patients with COVID (n=27) and influenza (n=35) in comorbidity with T2D, hypertension, and NASH. Overweight in 55 33 patients (53.2%) with BMI 28.14±0.39 kg/m², and 29 patients without overweight with BMI 56 23.37 ± 0.38 kg/m². T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); 57 NASH in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients 58 with NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). 59 Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss 60 during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; 61 62 systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan.

Results: The patients with overweight lost -12,4% from baseline or BMI= -4.2 kg/m², and patients without overweight lost -9,14% from baseline or BMI= -2.2 kg/m² (-9.7 \pm 0.7 kg vs. -6.4 \pm 0.6 kg, respectively; *P*<0.001) at 14-day of the treatment. Weight loss in both groups was due to reduction of fat mass (*P*<0.0001).

57 Sputum production increased in 1.0-1.5 liter/day on 2-3 days, decreased in 7-9 days. Body 58 temperature normalized in 6-9 days. On 3-5 days, in most patients their urine became 59 turbid/muddy/intensively colored. Urine microscopy showed organic and non-organic salts, and 50 leukocyturia (20-35/sight).

71 White blood cells, lymphocytes, NLR normalized at 14 days (P<0.0001). Total-fibrinogen, C-72 reactive-protein, and Erythrocyte-sedimentation-rate, ROS normalized at 14-day of treatment 73 (*P*<0.0001).

COVID and Influenza were a negative in >96.3% patients at 14-day. Systolic/diastolic BP decreased (161.3 \pm 1.31/101.6 \pm 0.85 vs. 118.3 \pm 0.46/80.89 \pm 0.66, *P*<0.0001), glucose and lipids metabolism in patients with T2D (n=26) (P<0.0001); ALT and AST in patients with NASH

77	(n=51) were significantly normalized (from baseline 134.3 \pm 5.4 and 166.5 \pm 5.5 U/L, respectively,
78	and at 14-day to 78.4 \pm 4.2 and 92.4 \pm 4.9 U/L, respectively (P<0.0001)), platelets increased from
79	baseline (186.5±4.6, ×10 ⁹ /L) at 14-day of treatment (238.5±5.8, ×10 ⁹ /L) (<i>P</i> <0.0001), and at 6-
80	week follow-up (278.3 \pm 6.9, ×10 ⁹ /L) (<i>P</i> <0.0001). The mean score of chest-CT for the patients
81	(n=44) was 13.12±0.38 from baseline, and at 14-day the score was 1.72±0.12 (<i>P</i> <0.0001).
82	ROS level normalized at 14-day treatment and 6-week follow-up from baseline (P<0.0001).
83	The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other
84	symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-
85	8 days treatment.
86	Conclusions: The fast weight loss is clinical/laboratory benefit in treatment of patients with
87	COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH.
88	Trial Registration: ClinicalTrials.gov NCT05635539. Registered 1 December 2022.
89	Keywords: COVID, Influenza, type 2 diabetes mellitus; hypertension, NASH, fast weight loss;

90 inflammation/glycemic/lipid profile; chest CT; lipid/protein oxidation.

91 **1. INTRODUCTION**

SARS-CoV-2, a virus which causes the disease known as COVID-19 (further – COVID), was 92 first described in a case of pneumonia of unknown origin in Wuhan City, China but guickly 93 94 evolved into a worldwide pandemic, and has changed the mortality rate. (1-3) COVID and Influenza are the most common acute respiratory diseases (ARD) in the world, which can 95 quickly spread through the air and direct contact. (2, 4, 5) The ARDs are serious illnesses that 96 >100 millions of people in the worldwide get each year. It sends millions of people to the 97 hospital and causes millions of deaths. (6, 7) The increased ranking of COVID as a leading 98 cause of death in some age groups is consistent with a downward age shift in the distribution 99 of COVID deaths in last years. (3, 8) 100

101 COVID and Influenza co-infection with other non-communicable chronic diseases (NCDs) 102 complicate the diagnosis, treatment, prognosis of the ARDs emerge new concern. (9, 10) This 103 comorbidity may even increase the disease symptom and mortality rate. Aggravating affects 104 of the ARDs on cardiovascular comorbidities, diabetes onset, and chronic liver and kidney 105 diseases have long been debating. (11, 12) Older age and type 2 diabetes (T2D), hypertension, 106 liver and kidney diseases were significantly associated with an increased likelihood of 107 mortality. (13) NCDs are also leading cause of mortality and morbidity in the world. (14, 15)

Pharmacology treatment of ARDs and NCDs evidenced positive results, but it is still insufficiently, due to many problems related with their effectiveness, wide side-effects, sensitivity and specificity, etc. (14, 16, 17) Vaccination for controlling COVID and Influenza infectious diseases continues to be the most effective method. Nonetheless, COVID and Influenza variants continue to evolve and emerge, resulting in significant public concerns worldwide. (3, 18)

Pharmacologic and bio-vaccine treatment are not always can help to cure the ARDs due to they have a lot of side effects during and post treatment period. Treatment of the ARDs is more difficult in patients with comorbidities as T2D, hypertension, and nonalcoholic steatohepatitis

(NASH). (19-21) Therefore, searching reliable, secure, and natural methods for treatment of
COVID and Influenza are continuing in the worldwide. (3, 5, 17, 18, 22)

NCDs and COVID are spreading in countries with a higher rate of overweight. (10, 23-27) The 119 120 Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy (CALERIE) phase 2 trial showed that moderate reduction of energy intake averaging approximately 12% 121 over 2 years could improve markers of inflammation, cardiometabolic health, and oxidative 122 stress in humans. (28, 29) Caloric restriction has been shown to extend life span and health 123 span in many animal species (30) There has been growing interest in evaluating related 124 strategies, such as intermittent fasting, periodic fasting, and time-restricted eating that may 125 achieve the putative benefits of caloric restriction with greater likelihood of sustainability. (31) 126 COVID affects different people in different ways. Most infected people will develop mild to 127 128 moderate illness and recover without hospitalization. Some studies reported a high prevalence of overweight and obesity in patients experiencing a severe COVID course, with serious 129 complications requiring hospitalization and admission to intensive care units. (27) Patients with 130 131 obesity require regularly taking medications for the treatment of any concurrent chronic diseases, their physicians must promptly manage any medical symptoms in the case 132 of suspected acute respiratory syndrome infection to prevent the risk of severe outcomes. (32) 133 ARDs with overweight are associated with an increase in oxidative stress and a decrease in 134 antioxidant protection. (23) Acute inflammation in patients with overweight extreme difficulties 135 in treatment and highlight the need for preventive measures. (33) 136

Pharmacological treatment of ARDs with NASH is a great challenge for medicine, because the
patients are often limited to take medicine due to persistent progression, increasing of
hepatocellular injury/ inflammation, and medicinal overloading. (20)

In previous studies we showed a significant impact of overweight/obesity prevalence on the increase in COVID morbidity/mortality, (26) and beneficial role of our weight loss method in improving glycemic, lipid and hormone profiles, electrolyte and biochemical indices, blood

pressure, reactive oxygen species and bone mineral density in patients with T2D, hypertension, and severe NASH. (34, 35) The aim of the study was: to evaluate the effects of our fast weight loss method on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) level and body composition in patients with COVID and Influenza in comorbidity with T2D, hypertension, and NASH.

148 2 STUDY DESIGN AND PARTICIPANTS

Study Design. A 6-week, open, pilot prospective clinical trial with the intention-to-treat principle. 149 2.1 Participants The study enrolled 72 adult people (38 women) aged from 25 to 80 years with 150 moderate-to-severe cases COVID and Influenza in comorbidity with NCDs as T2D, 151 hypertension, and NASH; 6 patients were excluded due to noncompliance of inclusion and 152 exclusion criteria. Of the remaining 66 patients 4 patients (6.5%) dropped out prior to the study 153 completion: 2 patients refused the treatment method in 3 days after starting, and 1 patient 154 155 moved to another city, 1 patient was excluded due to noncompliance. (Fig. 1) A control pharmacology group was not used because medicinal treatment was unacceptable due to 156 NASH in most of the patients. Thus, 62 patients (36 women) included for the analysis; 27 157 patients with COVID and 35 patients with Influenza. Overweight in 33 patients (53.2%) with 158 body mass index (BMI) 28.14±0.39 kg/m², and 29 patients without overweight with BMI 23.37 159 ± 0.38 kg/m². T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); NASH 160 in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients with 161 NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). Thus, 162 all patients with the ARDs had in comorbidity with one or more NCDs. All patients with T2D 163 were on Metformin, Sulfonylurea, DPP-4 inhibitors, GLP-1 receptor agonists, Glitazones in 164 different combinations. All patients with hypertension received antihypertensive treatment. 165 166 All patients refused for pharmacology therapy due to: either previous unsuccessful drug results; or an antimicrobial resistance profile; or drug allergy; or reluctance to take medication; 167

168 or iatrogenic fear (iatrophobia); or a rich failed experience in drug treatment; and NASH.

All the patients were admitted into the out-patient department in 3-5 days after illness onset.
The participants were recruited gradually as they come in the Republican Diagnostic Center at
University Medical Center (Astana) and ANADETO medical center from November 2020 to
March 2022. The study was carried out in the Republic of Kazakhstan from November, 2020,
through July, 2022.

174 *Inclusion criteria*: 1) written informed consent form; 2) patients with fever; 3) patients refused

for pharmacology therapy; 4) weight loss treatment for 12-14 days and +4 weeks follow-up (total 6 weeks).

177 *Exclusion criteria*: 1) patients with acute respiratory failure and assisted ventilation 178 requirement; 2) respiratory rate \geq 30 times per minute; 3) oxygen saturation \leq 93% by finger 179 oximetry at resting status.

Outcome measures Primary endpoints: Clinic and infectious tests for COVID and Influenza; weight loss during 14 days; inflammation profile. Secondary endpoints: fasting blood glucose, glycosylated hemoglobin A1c (HbA1c), blood insulin; systolic/diastolic blood pressures (BP); blood lipids; alanine aminotransferase (ALT), aspartate aminotransferase (AST), chest computed tomography (CT) scan.

185 **2.2 Analytical Assessment**

186 **Pathogen detection methods.**

Infection detection. COVID was diagnosed primarily by direct detection of SARS-CoV-2 RNA by nucleic acid amplification tests with a real-time reverse-transcriptase-polymerase-chainreaction (RT-PCR) assay using nasal or pharyngeal swab specimens from the upper respiratory tract. A health care professional collected a fluid sample by inserting a long nasopharyngeal swab into a nostril and taking fluid from the back of a nose.

192 To diagnosis of the flu was used a RT-PCR test called the Flu SC2 Multiplex Assay. Sputum

193 DNA was extracted using Chemagic DNA kits (PerkinElmer, Turku, Finland) and PCR assays

were performed using Seeplex Pneumobacter ACE Detection kits (Seegene Inc., Seoul, South

Korea) according to the manufacturer protocol. (36)

196 Sputum specimens collection, samples transport, samples storage, diagnostic test 197 procedures environment, to tests results reporting, every step were strictly performed under 198 the standard guidelines. (37, 38)

199 All the tests were performed in two independent laboratories in Astana: BioLab laboratory and OLIMP laboratory. Positive results were considered when both laboratories give equal results. 200 Biochemical laboratory assessments consisted of a complete blood cell count, white blood cells 201 (normal: 3.5-9.0×10⁹/L), neutrophil-to-lymphocyte ratio (NLR) is calculated by dividing the 202 absolute count for neutrophils by the absolute count for lymphocytes (normal: 1-2), blood 203 chemical analysis, erythrocyte sedimentation rate, urea (normal: 2.1-7.7 mmol/L), creatinine 204 205 (normal: 53-115 µmol/L), glucose, cholesterol (normal: <5.4 mmol/L), triglyceride (normal: <1.69 mmol/L), high-density lipoprotein (HDL) (normal: >1.55 mmol/L), fibrinogen (normal: 2.0-206 4.0 g/L), hepatic enzyme levels (ALT, norm <36 U/L, AST, norm <40 U/L), assessment of liver 207 208 and renal function, and measures of inflammation level, C-reactive protein (normal: ≤10.0 mg/L), and HbA1c (normal: <5.7%; prediabetes: 5.7-6.5%, diabetes: ≥6.5%). All the data of 209 enrolled cases, including demographic information, clinical symptoms or signs, clinical 210 outcomes and laboratory findings on admission, were included in electronic medical records. 211

Hormonal assays. Fasting serum insulin was determined by immunoassay (Immunotech
 Insulin Irma kit, Prague, Czech Republic). Hyperinsulinemia was considered >12.5 nU/L. The
 Homeostasis Model Assessment insulin resistance indexes (HOMA-IR) was used as surrogate
 measure of insulin sensitivity as follows: HOMA-IR = ((fasting insulin in nU/L) × (fasting glucose
 in mmol/l)/22.5). Insulin resistance was considered if the index was >2.

Diagnostic criteria for T2D were used the standards of American Diabetes Association in 2017.
 (39) Hypertension was diagnosed by BP readings and from medical records. Physical activity

of patients was assessed by the number of steps measured by pedometers (Hoffmann-La
Roche Ltd, Basel, Switzerland).

The Nonalcoholic Steatohepatitis Clinical Research Network criteria was used to diagnose
 NASH and from medical records. (40)

223 Anthropometrical data. Anthropometrical indicators included age (years), weight (kg), BMI (kg/m²). Body composition parameters including fat mass (in % of total body weight and total 224 kg), fat free mass (kg), total body water (%), muscle mass (%), and bone mass (%) were 225 measured using a Tanita-SC330S Body Composition Analyzer (Tanita Corp., Tokyo, Japan). 226 For ROS we measured malondialdehyde (MDA, a marker of lipid peroxidation and degradation 227 product of oxidized fatty acids), superoxide dismutase (SOD) and catalase (antioxidant 228 enzymes), and advanced oxidation protein products (AOPP, markers of protein oxidation). 229 230 MDA (µmol/L) was measured using a thiobarbituric acid-reactive substance assay as described by Yagi and modified by Ohkawa. (41) 231

Antioxidant enzymes were determined in erythrocyte hemolysates, in which hemoglobin 232 concentration was assayed using Drabkin's method. Superoxide dismutase was measured by 233 the method of Misra and Fridrovich. (42) Catalase was measured at λ =240 nm at 25 °C; 234 catalase activity was expressed in U/g and one unit is considered as the amount of the enzyme 235 which decomposes 1 g of H_2O_2 in 1 min at 25 °C in pH =7.0. AOPP (µmol/L) were measured 236 by adding 40 µL of plasma to a 190 µL of mixture of 81% phosphate buffer solution, 10% glacial 237 acetic acid and 4% 1.16 mmol solution of KI, followed by 2 minutes absorbance at 340 nm on 238 a plate reader Multiscan Ascent using a spectrophotometric method. Chloramine-T solution 239 was used as calibrator. (43) 240

Imaging. Ultrasound images (GE Vivid 9 Ultrasound; GE Healthcare Worldwide USA, Michigan) and chest CT (Siemens Somatom Sensation 32) were obtained. The key imaging finding in the pneumonia were ground-glass opacity, distribution and extent of lung abnormalities, including consolidation, cavitation and pleural effusion.

245 Chest CT assessment of the severity of lung changes. Each lung field was divided into three equal zones. Each zone was assigned a score from 0-4 based on the percentage of lung 246 involved (0 = no abnormality, $1 = \langle 25\% \rangle$ of the zone involved, 2 = 25-50% involved, 3 = 51-247 248 75% involved and 4 = >75% involved). The scores for all six zones of each CT examination were summed to provide a cumulative chest radiographic score (range, 0-24). (44, 45) 249 Baseline and follow-up CT scans were reviewed in consensus by two radiologists with 10-25 250 years of experience. Laboratory tests, ultrasound and CT images, and an electrocardiogram 251 were performed, and sputum and blood samples were collected on the inclusion day. 252

Intervention. We used the "Analimentary detoxication" (ANADETO) weight loss method, 253 including calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and 254 cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, 255 256 walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. 257 The weight loss method lasted 14 days. (46-48) Then the patients followed for 4-week a diet 258 259 where they ate one meal a day without any food restriction. A combination of in-person conversations and telephone calls were conducted during whole 6-week study period. 260

Ethics. The Local Ethics Committee of the University Medical Center (phone: +71272-692586; 261 e-mails: mirgul.bayanova@umc.org.kz; https://umc.org.kz/en/?ethics-commission) approved 262 the study "The fast weight loss in patients with acute and chronic respiratory infections in 263 comorbidity with non-communicable diseases" (approval protocol number is #7 of 26.09.2019). 264 Statistics The two-side Student's t-test and Odds ratios (ORs) with 95% Confidence intervals 265 (CIs) were used. The study data were tested against the normal distribution and are presented 266 267 in Tables as Mean±Standard Error of the Mean (M±SEM). P-value of <0.05 was set as significant and <0.0001 was set as highly significant. Statistical analysis was performed using 268 SPSS ver.23.0 for Windows (SPSS: An IBM Company, Armunk, NY) and Microsoft Excel-2021. 269 All analyses were intention-to-treat. 270

271 **Trial Registration:** ClinicalTrials.gov NCT05635539. Registered 1 December 2022.

272 **3 RESULTS**

The symptoms of COVID and Influenza were the common typical such as fever in 62 patients 273 (100%), cough in 48 (77.4%), runny or stuffy nose in 51 (82.2%), fatigue in 49 (79%), chills in 274 275 30 (48.4%), sore throat in 14 (22.6%), headache in 22 (35.4%), body aches in 18 (29%). Loss of taste or smell was in 21 patients (33.8%): 9 patients with COVID: 12 patients with Influenza. 276 This symptom did not differ between these diseases (95%; OR 0.96, CI 0.34-2.73, P=0.46). 277 Loss of appetite and smell irritability were in 51 patients (82.3%): 24 patients with COVID; 26 278 patients with Influenza (95%; OR 1.19, CI 0.81-1.77, P=0.92). Other clinical symptoms of the 279 diseases did not also differ from each other. 280

Baseline/ 7-day/ 14-day treatment and to 6-week follow-up results concerning anthropometrical data, body composition, and metabolic data are shown in **Table 1**. Patients with overweight lost from 8 to 11 kg (-12,4% from baseline), and it was higher than patients without overweight (-9,14% from baseline; -9.7±0.7 kg vs. -6.4±0.6 kg, respectively; *P*<0.001) at 14-day of the treatment. In patients with overweight BMI at 14-day was highly significantly decreased (-4.2 kg/m²) than in patients without overweight (-2.2 kg/m²) (*P*<0.001).

Weight loss in both groups was due to reduction of fat mass (P<0.0001). Percentages of total body water and muscle mass tended to increase significantly in both groups at 7-day/14-day of the treatment, and the percentage of bone mass increased significantly too (in patients with overweight P<0.0001; in patients without overweight P<0.05). Lean body mass (fat free mass) did not change significantly during weight loss in both groups, patients with and without overweight (P = 0.82-0.97). These trends persisted at 6-week of follow-up.

293 Starting from 2-3 days of the treatment, in almost patients is increased a sputum production to

1.0-1.5 liters a day. A sputum production decreased by 7-9 days of the treatment.

Body temperature decreased starting from 3-4 days of treatment, and it is normalized to 6-9

days, and also was normal at 6-week follow-up (Table 2). Begin from 3-5 days of the treatment,

in most of the patients their urine became turbid, muddy and intensively darkly colored, which persisted for several days. Urine microscopy showed organic and non-organic salts such as oxalates, urates, phosphates, and carbonates of calcium and magnesium, and leukocyturia (20-35 per in sight). Starting from 5-7 days of the treatment, the patients noticed a physical relief, increase in physical/mental workability, and exercise tolerance. Infection detection at 14day of treatment was a negative in 26 patients with COVID of 27, and 34 patients with Influenza of 35. Re-detection on the next two days showed a negative in both patients.

The weight loss treatment evoked significantly rising of serum urea and creatinine on 7-day of 304 treatment. We noticed normalization levels of serum urea and creatinine on 14-day. (Table 2) 305 During lipolysis on the weight loss treatment there was no protein lost because total serum 306 protein level significantly increased from baseline (62.41±0.53 g/l) to 14-day treatment 307 308 (66.92±0.65 g/l, P<0.0001), and 6-week follow-up (71.43±0.67 g/l, P<0.0001). Hemoglobin level also significantly increased from baseline (128.6±0.71 g/l) to 14-day treatment 309 (131.7±0.72 g/l, P<0.05), and 6-week follow-up (136.9±0.78 g/l, P<0.0001). HDL significantly 310 311 increased from baseline (0.96±0.03 mmol/L) to 14-day treatment (1.06±0.03 mmol/L, P=0.02), and 6-week follow-up (1.68±0.04 mmol/L, P<0.0001). (Table 2) 312

White blood cells were gradually decreased on the 14 day. Relative lymphocyte count increased that the NLR was significantly decreased (P<0.0001). Total fibrinogen, C-reactive protein, and Erythrocyte sedimentation rate were significantly decreased to normal at 14-day of treatment (P<0.0001) and 6-week follow-up (P<0.0001). (**Table 2**)

The weight loss treatment led to a normal systolic/diastolic BP starting from 7-day of treatment, and it were normalized at 14-day and 6-week follow-up (**Table 2**) reaching the levels recommended by the American Heart Association (2014).

The positive changes in glucose metabolism in patients with T2D (n=26) were at 14-day of treatment and also at 6-week follow-up. Fasting Glucose and Immunoassay Insulin, and HOMA-IR index quickly decreased at 14-day of treatment. Insulin decreased 2.3-fold from

323 baseline at 14-day of treatment, whereas 3.5-fold from baseline at 6-week follow-up. HbA1c

- decreased to the normal by 6-week (4,86±0.08) by 31% (*P*<0.05).
- 325 Cholesterol and triglycerides are significantly increased by 17.2-6.4% and 68.8-62.7% from
- baseline at 7 and 14 days of the treatment, respectively.
- 327 In patients with NASH (n=51) ALT and AST levels were significantly decreased from baseline
- 328 (134.3±5.4 and 166.5±5.5 U/L, respectively) at 7-day (by 102.6±5.7 (*P*<0.05) and 126.3±5.9
- 329 U/L (P<0.0001), respectively); and 14-day (by 78.4±4.2 (P<0.0001) and 92.4±4.9 U/L
- 330 (P<0.0001), respectively). On the 6-week follow-up ALT and AST levels returned to normal
- 331 (*P*<0.0001). (**Table 2**)
- 332 Platelets in patients with NASH (n=51) significantly increased from baseline 186.5±4.6, ×10⁹/L
- at 14-day of treatment by 238.5±5.8, ×10⁹/L (*P*<0.0001), and at 6-week follow-up by 278.3±6.9,
 ×10⁹/L (*P*<0.0001).
- Abnormal chest imaging. CT-scans were abnormal in 44 patients (70.97%) aged >40 years
 old, including 8 patients with NASH, T2D and Hypertension; 6 patients with NASH and T2D;
 12 patients with T2D and Hypertension; 18 patients with NASH and Hypertension.
- CT findings included multiple small patchy shadows, centrilobular nodules and bronchial wall 338 thickening, interstitial inflammation, predominantly distributed in the peripheral of the lungs, 339 ground glass opacities and infiltrates in the lungs, bronchopneumonia patterns. The most 340 common finding was ground glass opacity (n=39; 88.6% including 25 patients with COVID), 341 342 not followed by consolidation. Pleural effusion and cavitation was not detected. Unilateral lung involvement (n=36; 81.8%) was more common than bilateral involvement (n=6; 13.6%). The 343 right/ left lower zones (n=34; 77.3%) were more commonly affected than the right/ left middle 344 (n=9; 20.5%). Multifocal distribution was more common (n=24, 54.5%) than unifocal distribution 345 (n=19, 43.2%). Chest CT scans were non-specific for the ARDs. 346

The mean score of chest CT for the patients (n=44) was 13.12 ± 0.38 . A significant positive changes was found on 14-day of treatment with the score 1.72 ± 0.12 (*P*<0.0001). There were

not found the lung abnormalities at 6-week follow-up (Table 2). By 14-day of treatment CT
scans showed that the scope of the lesions had been reduced, the density was gradually
decreased, the number of lesions decreased, and the ground glass opacities were absorbed.
There was no the 6-week risk of arterial thromboembolism and venous thromboembolism
among the patients with COVID or Influenza.
The oxidative products of lipids and proteins had a trend to normalize at 14-day treatment and

6-week follow-up, where MDA decreased by 31.7% at 14-day (P<0.0001) and by 48.4% at 6week from baseline (P<0.0001), AOPP decreased by 30.2% at 14-day (P<0.0001) and by 36.3% at 6-week from baseline (P<0.0001), and SOD increased by 66.9% (P<0.0001) and Catalase by 76.6% at 14-day (P<0.0001), and by 92.4% and 85.8%, respectively, at 6-week from baseline (P<0.0001) (**Table 2**).

As the clinical status of the patients was improving, the previous antidiabetic (patients with T2D, n=26), antihypertensive (patients with hypertension, n=38), anti-inflammatory and hepatoprotective (patients with NASH, n=51), and other symptomatic conventional medications were adequately decreased starting from 2-5 days of ANADETO treatment. By days of 5 to 8 after the treatment start, the drugs were stopped completely. There were no recurrence of T2D, hypertension, and NASH at 6-week follow-up.

366 **4. DISCUSSION**

Our data showed that the fast weight loss 'ANADETO' method (-12,4% fat loss in patients with overweight, and -9,14% fat loss in patients without overweight) at 14-day treatment and at 6week follow-up had a clinical, laboratory and imaging effectiveness in patients with COVID and Influenza in comorbidity with T2D, hypertension, and NASH.

The weight loss in patients with overweight goes faster than in patients without overweight. This an interesting finding in the physiology of weight loss might be explained by different structure of fat in people with and without overweight. (49) People who quickly weight gain can accumulate a lightweight body fat, and people who slowly weight gain can accumulate a dense

body fat. Some people cannot weight gain that possibly related with genotype, different fat
structure, or metabolic equivalent when the same amount of fat can give different calorie. (50,
51)

The weight loss improved an immunity of the patients by significantly increased in lymphocyte count and decreased in NLR. In fact, lymphopenia has also been associated with severe illness and poorer survival in COVID-19. (52, 53) In clinical practice, it was observed that in some non-survivors, the absolute value of lymphocytes decreases progressively while the white blood cell count gradually increases over time, resulting in a "divergence" between the absolute value of neutrophils and lymphocytes, that NLR, may be correlated with the progression and prognosis of this newly emerged disease. (54)

Our clinical study confirmed that weight loss significantly reduces inflammation biomarkers. (55, 56) Reducing inflammation through weight loss could be associated with reduced risk for cardiovascular disease and other obesity-associated chronic diseases. (28, 57) The weight loss has immunomodulatory effect, repealed insulin resistance, improved blood insulin, increased blood hemoglobin, and improved blood pressure. (58, 59) The weight loss method also decreased blood cholesterol/triglyceride, lipid/ protein oxidative products, and increased anti-oxidative enzymes.

Increased serum urea and creatinine during 14-day weight loss can testify about endogen intoxication related to active lipolysis. Adsorbed endogen organic toxins in adipocytes are eliminated through blood system during lipolysis. (60, 61) Increase in lipids (cholesterol and triglyceride) from baseline at 7 and 14 days of the treatment confirms the activity of lipolysis during the weight loss treatment.

More sodium ions are eliminated through urine in patients with acute respiratory inflammation in comorbidity with NCDs. (62, 63) Blood and urine sodium became normal on a weight loss due to elimination of metabolic pollutants from the body.

Improvements of liver function we noticed by decrease in ALT and AST levels and increase in
blood platelets, and serum total protein. Weight loss improves liver health, cardiovascular risk,
and quality of life, therefore some authors offer it as feasible treatment option for patients
with NASH. (64, 65)

The study evidenced that chest CT in the patients with COVID and Influenza are highly variable and nonspecific, that is considered with other authors. (66) Chest CT has been widely used during the COVID pandemic, which has a high sensitivity, about 60-97%, but low specificity (about 20-50%). (66, 67) Many radiology professional societies recommend against performing chest CT as a primary technique for the diagnosis of COVID pneumonia. (68) In patients with ARDs, CT findings should be interpreted in combination with a clinical context.

Overweight is a biological burden for the body, which consumes additional immunological, antitoxic, trophic, excretion function. (69) The ANADETO method metabolizes 'old lipids' with fat loss, decreases in inflammation, increases in immune response, improves of glucose and lipid metabolism, and liver functions. The patients experienced side effects related to symptoms of metabolic intoxication that is a common problem during weight loss. Adipose tissue absorbs different persistent organic pollutants, (70) and plays an important role in storing of different pollutants. (71)

The ability to accumulate adipose tissue is one of the most important adaptive mechanisms for

survival, but now we observe a steady increase in obesity and related diseases. (72, 73)

The fast weight loss method was a safe, well tolerated, and acceptable nutritional therapy option for patients with acute respiratory inflammation diseases in comorbidity with T2D, hypertension, and NASH. The optimal mix of caloric restriction, sodium intake, walking (at normal body temperature), and sexual self-restraint behavior would be an effective treatment method of ARDs (COVID and Influenza) in comorbidity with NCDs.

424 **5. CONCLUSIONS**

Thus, the fast weight loss 'ANADETO' cured clinical, laboratory, and instrumental data of inflammation, improved glucose and lipids metabolism, normalized systolic/diastolic BPs and NASH's biochemical outcomes, decreased reactive oxygen species, and allowed drugs reduction up to its complete withdrawal in patients with COVID and Influenza in comorbidity with T2D, hypertension, and NASH. The weight loss occurred only due to a decrease in fat mass.

430 Study limitation

- The study has several limitations. First, the study was short duration. Second, we did not study
 T-cell and B-cell subpopulation. Third, the clinical trial had approximately 13.9% of the
- 433 assigned population dropped out prior to completion. Fourth, the study was non-randomized,
- 434 non-controlled trial. Fifth, published studies about positive role of weight loss in patients with
- 435 COVID and Influenza in comorbidity with Non-communicable diseases are limited in scope and
- 436 number. Further randomized controlled trials with longer-term follow-up are needed to confirm
- 437 and extend the results of the study.

438 List of Abbreviations:

- ANADETO 'Analimentary detoxication' weight loss method
- AOPP advanced oxidation protein products
- AST aspartate aminotransferase
- BMI body mass index
- BP blood pressure
- CT Computed tomography
- COVID SARS-CoV-2, a virus which causes the disease known as COVID-19
- HbA1c glycosylated hemoglobin A1c
- HDL high density lipoprotein
- HOMA-IR Homeostasis Model Assessment for Insulin Resistance
- M±SD Mean ± standard deviation
- M±SEM Mean ± standard error of the mean
- MDA malondialdehyde
- NASH Nonalcoholic steatohepatitis

- NCDs non-communicable chronic diseases
- ROS reactive oxygen species
- SOD superoxide dismutase
- T2D type 2 diabetes mellitus

439 **DECLARATIONS**

440 Ethics approval and consent to participate. The Local Ethics Committee of the University

441 Medical Center (phone: +71272-692586; e-mails: mirgul.bayanova@umc.org.kz;

- 442 https://umc.org.kz/en/?ethics-commission) approved a study "The fast weight loss in patients
- 443 with acute and chronic respiratory infections in comorbidity with non-communicable diseases"
- 444 (approval protocol number is #7 of 26.09.2019).

445 **Consent for publication.** All authors of the manuscript affirm that they had access to the

- study data and reviewed and approved the final version.
- 447 **Conflict of Interest Disclosures:** The authors declare that they have no any competing

448 interests (financial, professional, or personals) that are relevant to the manuscript. We have

read and understood the journal policy on declaration of interests and have no interests to

450 declare. Dukenbayeva Bibazhar, coauthor, she is a director of the Medical center

451 'ANADETO', who participated in the study design, data interpretation, writing of discussion,

452 bibliography and paper review.

453 Availability of data and materials. First, the data is too large (> 2.8 GB). Secondly, we will

454 make our data available to any investigator/reviewer on their own request, so that the

- 455 personal privacy of our patients cannot be compromised.
- 456 **Funding sources:** This research was supported by Ministry of Education and Science of the
- 457 Republic of Kazakhstan (Grant for 2018-2021 years with trial registration AP05135241,

458 National Center for Scientific and Technical Information of the Republic of Kazakhstan. K.O.,

- 459 a PI of the project, is supported by the Ministry of health of the Republic of Kazakhstan,
- 460 **2020-2021**.

461 **Author contributions:**

KO: study design, collection of the clinical data, diagnosis and treatment of the patients, 462 bibliography review, statistical analysis, data interpretation, writing of the paper. AD: study 463 464 design, data collection, diagnosis and treatment of the patients, data interpretation, bibliography and paper review. Al: study design, data collection, writing the Introduction and 465 Methods, data interpretation, paper review. ZZ and MG: preparation of the statistical data in 466 Excel, collection of the clinical data, bibliography and paper review, data interpretation, 467 statistical analysis, writing of the Methods and Discussion, paper review. GB: study design, 468 data collection, writing the results and discussion, and paper review. AT: writing of the 469 discussion, statistical analysis, paper review. AN: collection of the clinical data, preparation of 470 statistical data in Excel, patient diagnosis, bibliography search and review. BD: study design, 471 472 data collection and interpretation, writing the discussion, bibliography and paper review. All authors read and approved the final manuscript. 473

474 ACKNOWLEDGMENTS

- The authors thank the Republican Diagnostic Center at University Medical Center and
- 476 ANADETO medical center in recruiting patients and collecting data for the study, and
- 477 technical assistance.

478 6. REFERENCES

- 479 1. Federation. WO. Covid-19 and obesity: the 2021 atlas.March 2021. 227 p.
- 480 2. Li CX, Noreen S, Zhang LX, Saeed M, Wu PF, Ijaz M, et al. A critical analysis of SARS-CoV-2
- 481 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.
- 482 Biomedicine & Pharmacotherapy. 2022;146.
- 483 3. Veronese N, Smith L, Di Gennaro F, Bruyere O, Yang L, Demurtas J, et al. Influenza Vaccination and
- 484 COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study.
 485 Vaccines. 2022;10(6).
- 486
 4. Bar-Yishay M, Yehoshua I, Bilitzky A, Press Y. Treatment outcomes of acute streptococcal tonsillitis
 according to antibiotic treatment. A retrospective analysis of 242,366 cases treated in the community. European
 Journal of General Practice. 2022;28(1):142-9.
- 489 5. Rahman MM, Bibi S, Rahaman MS, Rahman F, Islam F, Khan MS, et al. Natural therapeutics and
 490 nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology. Chemical
 491 Engineering Journal. 2022;446.
- 492 6. Fang YY, Ni JC, Wang Y, Yu JH, Fu LL. Risk factors for hospital readmissions in pneumonia patients:
 493 A systematic review and meta-analysis. World Journal of Clinical Cases. 2022;10(12):3787-800.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 494 7. Sozzi FB, Gherbesi E, Faggiano A, Gnan E, Maruccio A, Schiavone M, et al. Viral Myocarditis:
- 495 Classification, Diagnosis, and Clinical Implications. Frontiers in Cardiovascular Medicine. 2022;9.
- 8. Shiels MS, Haque AT, de Gonzalez AB, Freedman ND. Leading Causes of Death in the US During the
 COVID-19 Pandemic, March 2020 to October 2021. Jama Internal Medicine. 2022;182(8):883-+.
- 498
 9. Moreland A, Gillezeau C, Eugene A, Alpert N, Taioli E. Ecologic study of influenza vaccination uptake
 499 and COVID-19 death rate in New York City. Bmc Public Health. 2022;22(1).
- 500 10. Chetboun M, Raverdy V, Labreuche J, Simonnet A, Wallet F, Caussy C, et al. BMI and pneumonia
- 501 outcomes in critically ill covid-19 patients: An international multicenter study. Obesity. 2021;29(9):1477-86.
- Bolla AM, Loretelli C, Montefusco L, Finzi G, Abdi R, Ben Nasr M, et al. Inflammation and vascular
 dysfunction: The negative synergistic combination of diabetes and COVID-19. Diabetes-Metabolism Research
 and Reviews.
- Celik AI, Bezgin T, Baytugan NZ, Coskun R, Karaaslan MB, Cagdas M. Role of the coronary and non coronary cardiovascular findings on non-cardiac gated thoracic CT in predicting mortality in SARS-CoV-2
 infection. Clinical Imaging. 2022;89:49-54.
- 508 13. Moctezuma-Velazquez P, Miranda-Zazueta G, Ortiz-Brizuela E, Alberto Garay-Mora J, Fernanda
- Gonzalez-Lara M, Maria Tamez-Torres K, et al. NAFLD determined by Dallas Steatosis Index is associated
 with poor outcomes in COVID-19 pneumonia: a cohort study. Internal and Emergency Medicine.
 2022;17(5):1355-62.
- 511 2022, 17(5):1555 02.
 512 14. NCD NCDRFC. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since
 513 1080: a poplad analysis of 751 nonvelation based studies with 4.4 million participants (vol. 287, no. 1512, 2010).
- 513 1980: a pooled analysis of 751 population-based studies with 4.4 million participants (vol 387, pg 1513, 2016).
 514 Lancet. 2017;389(10068):E2-E.
- 515 15. NCD Risk Factor Collaboration (NCD-RisC)-Americas Working Group. Trends in cardiometabolic risk 516 factors in the Americas between 1980 and 2014: a pooled analysis of population-based surveys (vol 8, pg e123,
- 517 2020). Lancet Global Health. 2021;9(1):E23-E.
- 518 16. Al Noman A, Islam MS, Sana S, Mondal P, Meem RI, Rana S, et al. A review of the genome,

epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspects. Egyptian
Journal of Bronchology. 2021;15(1).

- 17. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F. Epidemiology, pathogenesis, clinical
 presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Review of Clinical
 Pharmacology.
- Park T, Hwang H, Moon S, Kang SG, Song S, Kim YH, et al. Vaccines against SARS-CoV-2 variants
 and future pandemics. Expert Review of Vaccines.
- 526 19. Shah H, Khan MSH, Dhurandhar NV, Hegde V. The triumvirate: why hypertension, obesity, and
- 527 diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetologica. 2021;58(7):831-43.
- 528 20. Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. European 529 Journal of Pharmacology. 2020;870.
- 530 21. Bouadma L, Mekontso-Dessap A, Burdet C, Merdji H, Poissy J, Dupuis C, et al. High-Dose
- 531 Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute 532 Hypoxemic Respiratory Failure The COVIDICUS Randomized Clinical Trial. Jama Internal Medicine.
- Azh N, Barzkar F, Motamed-Gorji N, Pourvali-Talatappeh P, Moradi Y, Azad RV, et al. Nonsteroidal
- anti-inflammatory drugs in acute viral respiratory tract infections: An updated systematic review. Pharmacology
 Research & Perspectives. 2022;10(2).
- 536 23. Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. COVID-19 and Obesity: Dangerous
 537 Liaisons. Journal of Clinical Medicine. 2020;9(8).
- 538 24. Czernichow S, Bain SC, Capehorn M, Bogelund M, Madsen ME, Yssing C, et al. Costs of the COVID-
- 539 19 pandemic associated with obesity in Europe: A health-care cost model. Clinical Obesity. 2021;11(2).
- 540 25. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, et al. Body Mass Index
- and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical
 Ventilation, and Death-United States, March-December 2020. Mmwr-Morbidity and Mortality Weekly Report.
- 543 2021;70(10):355-61.
- 544 26. Oshakbayev K, Zhankalova Z, Gazaliyeva M, Mustafin K, Bedelbayeva G, Dukenbayeva B, et al.
- 545 Association between COVID-19 morbidity, mortality, and gross domestic product, overweight/ obesity, non-

546 communicable diseases, vaccination rate: A cross-sectional study. Journal of infection and public health.

- 547 2022;15(2):255-60.
- 548 27. Valerio A, Nisoli E, Rossi AP, Pellegrini M, Todesco T, El Ghoch M. Obesity and higher risk for severe 549 complications of COVID-19: What to do when the two pandemics meet. Journal of Population Therapeutics and
- 550 Clinical Pharmacology. 2020;27(2):E31-E6.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 551 28. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, et al. Effect of 6-month
- 552 calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight
- individuals: A randomized controlled trial (vol 295, pg 1539, 2006). Jama-Journal of the American Medical
 Association. 2006;295(21):2482-.
- Mendelsohn AR, Larrick JW. Dietary Restriction: Critical Co-Factors to Separate Health Span from
 Life Span Benefits. Rejuvenation Research. 2012;15(5):523-9.
- Mattison JA, Colman RJ, Beasley TM, Allison DB, Kemnitz JW, Roth GS, et al. Caloric restriction
 improves health and survival of rhesus monkeys. Nature Communications. 2017;8.
- 561 32. Krishnan A, Prichett L, Tao XT, Alqahtani SA, Hamilton JP, Mezey E, et al. Abnormal liver
- chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World Journal
 of Gastroenterology. 2022;28(5):570-87.
- Siegers JY, Novakovic B, Hulme KD, Marshall RJ, Bloxham CJ, Thomas WG, et al. A High-Fat Diet
 Increases Influenza A Virus-Associated Cardiovascular Damage. Journal of Infectious Diseases.
- 566 2020;222(5):820-31.
- S67 34. Oshakbayev K, Dukenbayeva B, Togizbayeva G, Durmanova A, Gazaliyeva M, Sabir A, et al. Weight
 S68 loss technology for people with treated type 2 diabetes: a randomized controlled trial. Nutrition & Metabolism.
 S69 2017;14.
- 570 35. Oshakbayev K, Bimbetov B, Manekenova K, Bedelbayeva G, Mustafin K, Dukenbayeva B. Severe 571 nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized
- 572 clinical trial. Current Medical Research and Opinion. 2019;35(1):157-65.
- 573 36. Manual of Clinical Microbiology, 9th Ed. Manual of Clinical Microbiology, 9th Ed. 2007:1-2256.
- 574 37. Bruno LC. IQCP: Guideline and Helpful Tools for Implementation. Laboratory Medicine.
- 575 2016;47(4):E42-E6.
- 576 38. Jung CY, Choe YH, Lee SY, Kim WJ, Lees JD, Ra SW, et al. Use of serology and polymerase chain 577 reaction to detect atypical respiratory pathogens during acute exacerbation of chronic obstructive pulmonary 578 disease. Korean Journal of Internal Medicine. 2018;33(5):941-51.
- 579 39. Khunti K, Alsifri S, Aronson R, Berkovic MC, Enters-Weijnen C, Forsen T, et al. Impact of
- hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and
 insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice. 2017;130:121-9.
- 582 40. Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA, Nonalcoholic S.
- Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic
 Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
 Hepatology. 2019;70(2):522-31.
- 586 41. Ohishi N, Ohkawa H, Miike A, Tatano T, Yagi K. A NEW ASSAY-METHOD FOR LIPID
- 587 PEROXIDES USING A METHYLENE-BLUE DERIVATIVE. Biochemistry International. 1985;10(2):205-11.
- 588 42. Misra HP, Fridovich I. SUPEROXIDE-DISMUTASE POSITIVE SPECTROPHOTOMETRIC
- 589 ASSAYS. Analytical Biochemistry. 1977;79(1-2):553-60.
- 590 43. Witko-Sarsat V, Friedlander M, Khoa TN, Capeillere-Blandin C, Nguyen AT, Canteloup S, et al.
- Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic
 renal failure. Journal of Immunology. 1998;161(5):2524-32.
- 44. Al Umairi RS, Al Salmi I, Al Kalbani J, Kamona A, Al Tai S, Al Kindi F, et al. COVID-2019
- Pneumonia: Severity and distribution of lung changes observed on the initial chest X-ray as an indicator of final
 outcomes. Sultan Qaboos Univ Med J. 2022;22(1):98-105.
- 596 45. Filchakova O, Dossym D, Ilyas A, Kuanysheva T, Abdizhamil A, Bukasov R. Review of COVID-19
 597 testing and diagnostic methods. Talanta. 2022;244.
- 598 46. Oshakbayev KP, Alibek K, Ponomarev IO, Uderbayev NN, Dukenbayeva BA. Weight change therapy
 599 as a potential treatment for end-stage ovarian carcinoma. Am J Case Rep. 2014;15:203-11.
- 600 47. Oshakbayev K, Dukenbayeva B, Otarbayev N, Togizbayeva G, Tabynbayev N, Gazaliyeva M, et al.
- 601 Weight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized 602 clinical trial. Nutrition Journal. 2015;14:9.
- 603 48. Oshakbayev KP, Seidaliyeva AP, Togizbayeva GI, Gazaliyeva MA, Durmanova AK, Idrisov AS, et al.
- Clinical management with weight loss therapy in patients with Type 2 diabetes: a randomised clinical trial.
 Diabetic Medicine. 2016;33:32-.
- 606 49. Taylor R, Holman RR. Normal weight individuals who develop Type 2 diabetes: the personal fat threshold. Clinical Science. 2015;128(7):405-10.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.04.22283077; this version posted December 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 608 50. Doo M, Won S, Kim Y. Association between the APOB rs1469513 polymorphism and obesity is 609 modified by dietary fat intake in Koreans. Nutrition. 2015;31(5):653-8.
- 610 Mahmoudi-Nezhad M, Farhangi MA, Kahroba H. Cocaine and amphetamine-regulated transcript 51.
- 611 prepropeptide gene (CARTPT) polymorphism interacts with Diet Quality Index-International (DQI-I) and
- 612 Healthy Eating Index (HEI) to affect hypothalamic hormones and cardio-metabolic risk factors among obese
- 613 individuals. Journal of Translational Medicine. 2020;18(1).
- 614 52. Luo M, Liu J, Jiang WL, Yue S, Liu HG, Wei S. IL-6 and CD8(+) T cell counts combined are an early 615 predictor of in-hospital mortality of patients with COVID-19. Jci Insight. 2020;5(13).
- Diao B, Wang CH, Tan YJ, Chen XW, Liu Y, Ning LF, et al. Reduction and Functional Exhaustion of T 616 53. 617 Cells in Patients With Coronavirus Disease 2019 (COVID-19). Frontiers in Immunology. 2020;11.
- 618 54. Liu YP, Li GM, He J, Liu Y, Li M, Zhang R, et al. Combined use of the neutrophil-to-lymphocyte ratio
- 619 and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a
- 620 retrospective cohort study. Annals of Translational Medicine. 2020;8(10).
- 621 Jung DY, Ko HJ, Lichtman EI, Lee E, Lawton E, Ong H, et al. Short-term weight loss attenuates local 55. 622 tissue inflammation and improves insulin sensitivity without affecting adipose inflammation in obese mice.
- 623 American Journal of Physiology-Endocrinology and Metabolism. 2013;304(9):E964-E76.
- 624 Surendar J, Karunakaran I, Frohberger SJ, Koschel M, Hoerauf A, Hubner MP. Macrophages Mediate 56. 625 Increased CD8 T Cell Inflammation During Weight Loss in Formerly Obese Mice. Frontiers in Endocrinology. 626 2020:11.
- 627 57. Le Roux C, Aminian A, Batterham R, Hesse D, Jensen C, McGowan B, et al. Weight Loss Outcomes 628 with Semaglutide 2.4 mg in Moderate or Severe Obesity in STEP 1 and 2. Obesity. 2021;29:46-.
- 629 Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle Weight-Loss Intervention Outcomes 58.
- 630 in Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of
- 631 Randomized Clinical Trials. Journal of the Academy of Nutrition and Dietetics. 2015;115(9):1447-63.
- 632 59. Lorenzo PM, Sajoux I, Izquierdo AG, Gomez-Arbelaez D, Zulet MA, Abete I, et al. Immunomodulatory
- 633 effect of a very-low-calorie ketogenic diet compared with bariatric surgery and a low-calorie diet in patients 634 with excessive body weight. Clinical Nutrition. 2022;41(7):1566-77.
- 635 60. Konopelniuk VV, Goloborodko, II, Ishchuk TV, Synelnyk TB, Ostapchenko LI, Spivak MY, et al.
- 636 Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-637 calorie diet-induced obesity rat model-comparative study. Epma Journal. 2017;8(4):377-90.
- 638 Oshakbayev KP, Dukenbayeva BA, Idrisov AS, Oshakbayev P. Endogen metabolic intoxication at 61. 639 weight loss therapy in patients with metabolic syndrome. Diabetic Medicine. 2013;30:106-7.
- 640 62. Liamis G, Liberopoulos E, Barkas F, Elisaf M. Diabetes mellitus and electrolyte disorders. World 641 Journal of Clinical Cases. 2014;2(10):488-96.
- 642 Lee YM, Kim KS, Kim SA, Hong NS, Lee SJ, Lee DH. Prospective associations between persistent 63. 643 organic pollutants and metabolic syndrome: A nested case-control study. Science of the Total Environment. 644 2014;496:219-25.
- 64. Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, et al. Feasibility of a Very Low Calorie 645
- 646 Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. Clinical and 647 Translational Gastroenterology. 2020;11(9).
- 648 65. Schwenger KJP, Fischer SE, Jackson TD, Okrainec A, Allard JP. Non-alcoholic Fatty Liver Disease in
- 649 Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low 650 Calorie Diet. Obesity Surgery. 2018;28(4):1109-16.
- 651 66. Carlicchi E, Gemma P, Poerio A, Caminati A, Vanzulli A, Zompatori M. Chest-CT mimics of COVID-19 pneumonia-a review article. Emergency Radiology. 2021;28(3):507-18. 652
- 653 67. Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain 654 Reaction for Coronavirus Disease 2019: A Meta-Analysis. Radiology. 2020;296(3):E145-E55.
- 655 Ebrahimzadeh S, Islam N, Dawit H, Salameh JP, Kazi S, Fabiano N, et al. Thoracic imaging tests for 68. 656 the diagnosis of COVID-19. Cochrane Database of Systematic Reviews. 2022(5).
- 657 Dirinck EL, Dirtu AC, Govindan M, Covaci A, Van Gaal LF, Jorens PG. Exposure to Persistent 69.
- 658 Organic Pollutants: Relationship With Abnormal Glucose Metabolism and Visceral Adiposity. Diabetes Care. 659 2014;37(7):1951-8.
- Pestana D, Faria G, Sa C, Fernandes VC, Teixeira D, Norberto S, et al. Persistent organic pollutant 660 70.
- levels in human visceral and subcutaneous adipose tissue in obese individuals-Depot differences and 661
- 662 dysmetabolism implications. Environmental Research. 2014;133:170-7.
- 663 Lee DH, Porta M, Jacobs DR, Vandenberg LN. Chlorinated Persistent Organic Pollutants, Obesity, and 71. 664 Type 2 Diabetes. Endocrine Reviews. 2014;35(4):557-601.

- 665 72. Gribsholt SB, Cronin-Fenton D, Veres K, Thomsen RW, Ording AG, Richelsen B, et al. Hospital-
- diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort study. Journal of Internal 666 667 Medicine. 2020;287(4):435-47.
- 668 73. Gielen M, Hageman GJ, Antoniou EE, Nordfjall K, Mangino M, Balasubramanyam M, et al. Body mass
- 669 index is negatively associated with telomere length: a collaborative cross-sectional meta-analysis of 87
- observational studies. American Journal of Clinical Nutrition. 2018;108(3):453-75. 670

- Table 1 Anthropometrical data, body composition in patients (with/ without overweight) with
 673
- COVID and Influenza in comorbidity with the Non-communicable diseases before (baseline), 674
- during treatment, and 6-week follow-up (M ± SEM) 675

	Treatment days		6-Week follow-
Baseline			up
	7 day	14 day	
83.15 ± 0.74	76.24 ± 0.79**	72.84 ± 0.72**	74.18 ± 0.89**
28.14 ± 0.39	26.07 ± 0.37*	24.91 ± 0.34**	25.37 ± 0.35**
29.73 ± 0.45	22.90 ± 0.41**	19.54 ± 0.51**	21.94 ± 0.53**
58.21 ± 0.43	58.09 ± 0.41	58.08 ± 0.41	58.23 ± 0.44
53.47 ± 0.43	57.32 ± 0.42**	62.13 ± 0.44**	62.33 ± 0.45**
65.45 ± 0.98	69.89 ± 1.02*	74.67 ± 1.06**	74.54 ± 1.09**
3.61 ± 0.09	3.68 ± 0.09	3.83 ± 0.09	4.12 ± 0.09**
71.33 ± 0.81	67.98 ± 0.83*	64.81 ± 0.83**	66.12 ± 0.80**
23.37 ± 0.38	23.80 ± 0.37	21.23 ± 0.35*	22.15 ± 0.35*
25.81 ± 0.43	23.43 ± 0.41*	19.81 ± 0.43**	20.93 ± 0.39**
52.92 ± 0.52	52.05 ± 0.51	51.77 ± 0.48	52.28 ± 0.47
53.97 ± 0.46	55.22 ± 0.46	59.32 ± 0.48**	59.94 ± 0.48**
67.84 ± 0.97	68.76 ± 0.99	72.67 ± 0.98*	71.85 ± 0.98*
3.78 ± 0.08	3.80 ± 0.09	3.97 ± 0.08	4.09 ± 0.10*
	28.14 ± 0.39 29.73 ± 0.45 58.21 ± 0.43 53.47 ± 0.43 65.45 ± 0.98 3.61 ± 0.09 71.33 ± 0.81 23.37 ± 0.38 25.81 ± 0.43 52.92 ± 0.52 53.97 ± 0.46 67.84 ± 0.97	Baseline7 day 83.15 ± 0.74 $76.24 \pm 0.79^{**}$ 83.15 ± 0.74 $76.24 \pm 0.79^{**}$ 28.14 ± 0.39 $26.07 \pm 0.37^{*}$ 29.73 ± 0.45 $22.90 \pm 0.41^{**}$ 58.21 ± 0.43 58.09 ± 0.41 53.47 ± 0.43 $57.32 \pm 0.42^{**}$ 65.45 ± 0.98 $69.89 \pm 1.02^{*}$ 3.61 ± 0.09 3.68 ± 0.09 71.33 ± 0.81 $67.98 \pm 0.83^{*}$ 23.37 ± 0.38 23.80 ± 0.37 25.81 ± 0.43 $23.43 \pm 0.41^{*}$ 52.92 ± 0.52 52.05 ± 0.51 53.97 ± 0.46 55.22 ± 0.46 67.84 ± 0.97 68.76 ± 0.99	Baseline 7 day 14 day 83.15 ± 0.74 $76.24 \pm 0.79^{**}$ $72.84 \pm 0.72^{**}$ 83.15 ± 0.74 $76.24 \pm 0.79^{**}$ $72.84 \pm 0.72^{**}$ 28.14 ± 0.39 $26.07 \pm 0.37^*$ $24.91 \pm 0.34^{**}$ 29.73 ± 0.45 $22.90 \pm 0.41^{**}$ $19.54 \pm 0.51^{**}$ 58.21 ± 0.43 58.09 ± 0.41 58.08 ± 0.41 53.47 ± 0.43 $57.32 \pm 0.42^{**}$ $62.13 \pm 0.44^{**}$ 65.45 ± 0.98 $69.89 \pm 1.02^*$ $74.67 \pm 1.06^{**}$ 3.61 ± 0.09 3.68 ± 0.09 3.83 ± 0.09 71.33 ± 0.81 $67.98 \pm 0.83^*$ $64.81 \pm 0.83^{**}$ 23.37 ± 0.38 23.80 ± 0.37 $21.23 \pm 0.35^*$ 25.81 ± 0.43 $23.43 \pm 0.41^*$ $19.81 \pm 0.43^{**}$ 52.92 ± 0.52 52.05 ± 0.51 51.77 ± 0.48 53.97 ± 0.46 55.22 ± 0.46 $59.32 \pm 0.48^{**}$ 67.84 ± 0.97 68.76 ± 0.99 $72.67 \pm 0.98^*$

676

* *P*-value of < 0.05, and 677

** P < 0.0001 were set as significant from baseline. 678

679 Abbreviations: BMI, body mass index; M, mean; SEM, standard error of the mean.

680

- **Table 2** Body temperature, Blood pressures, Inflammation level, Glucose and Lipids
- 683 metabolism, Lipid and protein oxidative products, and chest CT in patients with COVID and
- 684 Influenza in comorbidity with the Non-communicable diseases at baseline, during treatment,
- 685 and 6-week follow-up (M ± SEM)

Variables (n)	Baseline	Treatment days		6-Week follow-
		7 day	14 day	up
Body temperature, °C (62)	39.34 ± 0.08	37.86 ± 0.08**	36.7 ± 0.05**	36.5 ± 0.03**
Systolic BP in patients with	161.3 ± 1.31	116.2 ± 0.77**	118.3 ± 0.46**	120.8 ± 1.17**
hypertension, mmHg (38)				
Diastolic BP in patients with	101.6 ± 0.85	78.92 ± 0.67**	80.89 ± 0.66**	81.23 ± 0.79**
hypertension, mmHg (38)				
Total protein, g/l (62)	62.41 ± 0.63		66.92 ± 0.65**	71.43 ± 0.67**
Hemoglobin, g/L (62)	128.6 ± 0.71		131.7 ± 0.72*	136.9 ± 0.78**
White blood cells, ×10 ⁹ /L (62)	12.29 ± 0.17	11.83 ± 0.16	7.68 ± 0.12**	5.21 ± 0.09**
Neutrophil, ×10 ⁹ /L (62)	7.128 ± 0.012	6.389 ± 0.010**	3.610 ± 0.009**	2.501 ± 0.012**
Lymphocytes, ×10 ⁹ /L (62)	2.581 ± 0.008	3.256 ± 0.009**	2.918 ± 0.009**	1.824 ± 0.008**
Neutrophil-to-lymphocyte ratio	2.762±0.009	1.962 ± 0.009**	1.237 ± 0.009**	1.371 ± 0.008**
(62)				
Erythrocyte sedimentation rate,	33.4 ± 0.56		13.76 ± 0.24**	7.59 ± 0.24**
mm/Hour (62)				
Total Fibrinogen, g/L (62)	4.83 ± 0.07	5.25 ± 0.09*	3.81 ± 0.08**	2.92 ± 0.09**
C-reactive protein, mg/L (62)	34.86 ± 1.26	26.35 ± 1.37**	12.39 ± 0.79**	6.57 ± 0.74**
Glucose in patients with T2D,	12.86 ± 0.19	6.75 ± 0.11**	4.60 ± 0.09**	4.58 ± 0.10**
mmol/L (26)				
HbA1c, % (26)	7.03 ± 0.09			4.86 ± 0.08**
Immunoassay Insulin, nU/L (26)	22.38 ± 0.58		9.61 ± 0.22**	6.45 ± 0.17**
HOMA-IR index (26)	12.79 ± 0.35		1.96 ± 0.17**	1.31 ± 0.17**
Platelets, ×10 ⁹ /L (51)	186.5 ± 4.6	196.6 ± 4.7	238.5 ± 5.8**	278.3 ± 6.9**

medRxiv preprint doi: https://doi.org/10.1101/2022.12.04.22283077; this version posted December 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. н

Э.

ALT, U/L (51)	134.3 ± 5.4	$102.6\pm5.7^{*}$	$78.4\pm4.2^{\star\star}$	$27.5 \pm 1.8^{**}$
AST, U/L (51)	166.5 ± 5.5	$126.3\pm5.9^{\star\star}$	$92.4\pm4.9^{\star\star}$	$29.3 \pm 1.8^{\star\star}$
Urea, mmol/L (62)	5.17 ± 0.07	7.54 ± 0.07**	5.62 ± 0.06**	4.14 ± 0.07**
Creatinine, µmol/L (62)	75.58 ± 1.27	109.73 ± 1.59**	62.86 ± 1.07**	58.45 ± 0.94**
Cholesterol, mmol/L (62)	5.82 ± 0.07	6.83 ± 0.08**	6.19 ± 0.09*	4.74 ± 0.07**
Triglyceride, mmol/L (62)	2.52 ± 0.07	5.94 ± 0.09**	5.73 ± 0.08**	1.11 ± 0.05**
HDL, mmol/L (62)	0.96 ± 0.03	1.02 ± 0.03	1.06 ± 0.03*	1.68 ± 0.04**
MDA, µmol/L (62)	60.74 ± 1.84		41.51 ± 0.87**	31.37 ± 0.86**
AOPP, µmol/L (62)	295.6 ± 9.2		206.3 ± 11.1**	188.3 ± 7.4**
SOD, U/mg (62)	34.58 ± 1.07		57.72 ± 1.06**	66.53 ± 0.98**
Catalase, U/g (62)	26.52 ± 0.67		46.83 ± 0.65**	49.29 ± 0.71**
Chest CT scan, score (44)	13.12 ± 0.38		1.72 ± 0.12**	0.0 ± 0.0

686

687 * *P*-value of < 0.05, and

688 ** *P* < 0.0001 were set as significant from baseline.

689 Abbreviations: AOPP, Advanced oxidation protein products; BP, blood pressure; CT, Computed 690 tomography; HDL, high density lipoprotein; HOMA-IR, Homeostasis Model Assessment for Insulin 691 Resistance; M, mean; MDA, Malondialdehyde; SOD, Superoxide dismutase; SEM, standard error of 692 the mean; T2D, type 2 diabetes.

Figure 1. Participant Flow Diagram



